BioSig Technologies awarded US patent claims for noise-filtering methods of signal processing technology

BioSig Technologies Inc (NASDAQ:BSGM) said that US Patent Office has allowed a utility patent covering its PURE EP noise-filtering technology. The medical technology firm, which specializes in commercializing a signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, said the patent describes and claims systems and methods for filtering noise during a quiet period. In particular, the patent involves filtering out harmonics and noise from an input cardiac signal. READ: BioSig CEO says PURE EP System is “gaining momentum” as it adds new healthcare facilities BioSig said with the patented filtering technology integrated into the PURE EP, raw signals acquired by an acquisition module are filtered and processed in accompanying software using a digital processing module, with minimal use of filters in the hardware. From a clinical perspective, the company said the patented PURE EP System can significantly assist a medical team's decision making for patients undergoing various medical therapies, with benefits including suppression of RF energy for cleaner, more reliable recordings of intracardiac signals, less wander, and noise reduction; improved dynamic range for better visualization, especially of very low amplitude signals temporally situated within large-amplitude signals; real-time digital processing and recording of raw signals to facilitate signal filtering without affecting original information and to reduce artifacts and noise. The firm also said the patent complements is expanding patent portfolio which now includes 34 issued or allowed worldwide patents as well as exclusive licenses to 16 additional worldwide utility patent applications from the Mayo Foundation for Medical Education and Research, three of which have been issued and/or have been allowed to date. "We are pleased to announce this newest patent allowance which demonstrates the clinical significance of our PURE EP System in filtering noise from complex cardiac signals in the electrophysiological setting”, BioSig chairman and chief executive Kenneth L. Londoner said in a statement. “The industry reports consistently indicate that inability to detect small intracardiac signals and difficulties to record high-quality signals account for some of the main factors that interfere with effective cardiac ablations. We believe that we have the leading patent-protected solution for ensuring signal clarity that is paramount to the success of cardiac ablations for all types of cardiac arrhythmias”, he added. Contact the author at calum@proactiveinvestors.com Follow him on Twitter @Cal_Proac